<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284151</url>
  </required_header>
  <id_info>
    <org_study_id>CYM6 Prostate CFB2</org_study_id>
    <nct_id>NCT03284151</nct_id>
  </id_info>
  <brief_title>Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma</brief_title>
  <official_title>Robotic and Focused Stereotactic Radiation Treatment of Good Prognosis Prostatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse, Luxembourg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse, Luxembourg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Focused stereotactic radiation treatment of localized prostatic adenocarcinoma. in order to
      quantify the delay between the focused treatment and the salvage procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Focused stereotactic radiation treatment of localized prostatic adenocarcinoma. in order to
      quantify the delay between the focused treatment and the salvage procedure.

      Second objectives : objectives: prostate-specific antigen (PSA) response, MRI response,
      toxicity (CTCAEv4), quality of life (International Prostate Symptom Score (IPSS) and The
      International Index of Erectile Function (IIEF5) scores).

      Method At first: Multiparametric Magnetic resonance imaging (MRI) - 12 biopsies within the
      whole gland.

      Placement under endorectal ultrasound control of 4 fiducials at least 2 cm spaced.

      Treatment : CyberKnife radiation treatment delivering 36.25 Gy in 5 fractions, in 10 days.
      Tracking using the 4 fiducials. Critical organs: Rectal and bladder wall: V35&lt;2cc. Bladder
      neck and urethra: V35&lt;1cc.

      Salvage treatments: in such a context, salvage surgery or salvage intensity modulation
      radiation therapy (IMRT) treatments can in theory remain valid and safe options.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Delay between the initial diagnosis and date of salvage treatment</measure>
    <time_frame>through study completion, up to 36 months</time_frame>
    <description>Delay between the initial diagnosis and date of salvage treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA evaluation</measure>
    <time_frame>3, 6, 12, 18, 24, 30, 36 months</time_frame>
    <description>PSA dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birads score evaluation</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>Multiparametric prostatic MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity</measure>
    <time_frame>3, 6, 12, 18, 24, 30, 36 months</time_frame>
    <description>Acute and late toxicity using the CTCAEv4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS evaluation</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>IPSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF5 evaluation</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>IIEF5 score</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cyberknife</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prostatic adenocarcinoma Capra≤2
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostatic adenocarcinoma of Capra score≤2 invading no more than two adjacent of the 12
             prostatic zones. Lesions&gt;3mm. Maximal urinary flow rate ≥ 10ml/s, mean flow rate ≥
             5ml/s, post micturation volume ≤80ml, IPSS score ≤15.

        Exclusion Criteria:

          -  systemic disease, ulcerative hemorrhagic ulcer or Crohn diseases, bladder neck
             stenosis, urethral implants, transurethral prostatectomy (TURP), any recurrent
             prostatitis within the last 3 years.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Nickers, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Francois Baclesse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Untereiner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Francois Baclesse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Nickers, MD, PhD</last_name>
    <phone>00352571167200</phone>
    <email>philippe.nickers@baclesse.lu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Lieunard</last_name>
    <phone>00352571167200</phone>
    <email>charlotte.lieunard@baclesse.lu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Esch Sur Alzette</city>
        <zip>4005</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>good prognosis</keyword>
  <keyword>focused treatment</keyword>
  <keyword>Cyberknife</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

